J
Janux Therapeutics D
D
JANX
50.600
USD
4.07
(8.75%)
Market Closed
Volume
29,242
EPS
-1
Div Yield
-
P/E
-43
Market Cap
2,655,590,212
Novo Nordisk Surges in Profit and Sales
6 months ago
Stocks news More
Title: Janux Therapeutics
Sector: Healthcare
Industry: Biotechnology
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.